Cogent Biosciences, Inc. Deferred Tax Assets, Deferred Income
Cogent Biosciences, Inc. (COGT) had Deferred Tax Assets, Deferred Income of $3.29 million as of 2018-12-31, per its 10-K filed 2020-03-26.
Discontinued › Notes › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsDeferredIncome · last filed 2020-03-26
- 2018-12-31: Deferred Tax Assets, Deferred Income $3.29M.
- 2017-12-31: Deferred Tax Assets, Deferred Income $3.69M.
| Period end | Deferred Tax Assets, Deferred Income |
|---|---|
| 2018-12-31 | $3.29M 10-K · filed 2020-03-26 |
| 2017-12-31 | $3.69M 10-K · filed 2019-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |